Network Version
TAS-301 Data Sheet
| Product Name: | TAS-301 |
 |
|---|---|---|
| CAS No.: | 193620-69-8 | |
| Cat. No.: | HY-18965 | |
| MWt: | 357.4 | |
| Formula: | C23H19NO3 | |
| Purity : | >98% | |
| Solubility: | DMSO : ≥ 38 mg/mL (106.32 mM) | |
| Mechanisms: | Target: Cardiovascular Disease | |
| Biological Activity: | ||
| TAS-301 is an inhibitor of smooth muscle cell migration and proliferation, and inhibits PKC activation induced by PDGF. IC50 & Target: PKC[1] In Vitro: TAS-301 (1-10 μM) concentration-dependently inhibits PKC activation and Ca2+ influx, induced by PDGF, with 62.7% inhibition on PKC activation at 10 μM, and reduces PMA-induced AP-1, with 38% and 67.6% inhibition at 3 and 10 μM, respectively[1]. TAS-301 (0.3-3 μM) dose-dependently reduces the migration of cells induced by growth factors (PDGF-BB, IGF-1,HB-EGF). TAS-301 (1-10 μM) also decreases bFGF-induced BrdU incorporation, especially at 3 and 10 μM[2]. In Vivo: TAS-301 (3-100 mg/kg, p.o.) dose-dependently reduces the neointimal thickening and I/M ratio and decreases the level of intimal cells in rats 14 days after balloon injury[2]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com